6/1/22

Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, June 3-7, 2022